Suppr超能文献

用于治疗颅面多汗症的新型内镜胸交感神经切除术的早期结果

Early results of new endoscopic thoracic sympathectomy for craniofacial hyperhidrosis.

作者信息

Moon Duk Hwan, Kang Du-Young, Kim Dong Won, Kang Min Kyun, Lee Sungsoo

机构信息

Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Department of Cardiovascular and Thoracic Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

J Thorac Dis. 2018 Jun;10(6):3627-3631. doi: 10.21037/jtd.2018.05.190.

Abstract

BACKGROUND

Endoscopic thoracic sympathectomy (ETS) has been considered as a definitive treatment for hyperhidrosis. However, despite its well-established success rate, surgical treatment for craniofacial hyperhidrosis (CFH) is rarely performed due to the possibility of fatal complications and compensatory sweating. The aim of this study was to evaluate the safety and efficacy of our newly developed method of ETS for CFH, based on early results.

METHODS

Between June 2016 and October 2017, a total of 70 patients underwent ETS with our new technique for CFH. All patients were placed under double-lumen intubation anesthesia with CO2 gas installation. We utilized two ports, one for 2-mm endoscope and another for 3-mm instrument. Our technique involved R2 and R4-R7 sympathectomy with R4-R7 truncal ablation.

RESULTS

There were 55 males and 15 females, with a mean age of 48 years (range, 22-75 years). The median operation time was 38 minutes (range, 28-75 minutes). There was no operative mortality and morbidity. During the short follow-up period (average 7 months; range, 1-17 months), symptoms were improved in all patients and compensatory hyperhidrosis was observed 68 patients: mild in 50 patients (71.4%), moderate in 13 patients (18.6%), and severe in 5 patients (7.1%).

CONCLUSIONS

In select patients, our technique of ETS appears to be a safe and effective treatment method for treating CFH. However, a study with long-term follow-up is still necessary to confirm our findings.

摘要

背景

内镜下胸交感神经切除术(ETS)一直被视为治疗多汗症的确定性疗法。然而,尽管其成功率已得到充分证实,但由于存在致命并发症和代偿性出汗的可能性,很少进行颅面部多汗症(CFH)的手术治疗。本研究的目的是根据早期结果评估我们新开发的ETS治疗CFH方法的安全性和有效性。

方法

2016年6月至2017年10月期间,共有70例患者接受了我们用于CFH的新技术ETS治疗。所有患者均在双腔插管麻醉下并安装二氧化碳气体。我们使用了两个端口,一个用于2毫米内窥镜,另一个用于3毫米器械。我们的技术包括R2和R4 - R7交感神经切除术以及R4 - R7干切断术。

结果

男性55例,女性15例,平均年龄48岁(范围22 - 75岁)。中位手术时间为38分钟(范围28 - 75分钟)。无手术死亡和并发症。在短期随访期间(平均7个月;范围1 - 17个月),所有患者症状均有改善,68例患者出现代偿性多汗:50例患者为轻度(71.4%),13例患者为中度(18.6%),5例患者为重度(7.1%)。

结论

在特定患者中,我们的ETS技术似乎是治疗CFH的一种安全有效的治疗方法。然而,仍需要进行长期随访研究以证实我们的发现。

相似文献

引用本文的文献

本文引用的文献

2
Endoscopic thoracic sympathectomy.内镜下胸交感神经切除术
Dermatol Clin. 2014 Oct;32(4):541-8. doi: 10.1016/j.det.2014.06.007. Epub 2014 Jul 21.
4
Botulinum toxin B in the treatment of craniofacial hyperhidrosis.肉毒杆菌毒素B治疗颅面部多汗症
J Eur Acad Dermatol Venereol. 2014 Oct;28(10):1313-7. doi: 10.1111/jdv.12278. Epub 2013 Oct 3.
8
Evidence-based review of the nonsurgical management of hyperhidrosis.
Thorac Surg Clin. 2008 May;18(2):157-66. doi: 10.1016/j.thorsurg.2008.01.004.
10
An epidemiological study of hyperhidrosis.多汗症的流行病学研究。
Dermatol Surg. 2007 Jan;33(1 Spec No.):S69-75. doi: 10.1111/j.1524-4725.2006.32334.x.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验